Chronic Hepatitis B

Famciclovir is the well-absorbed (77% bioavailability) oral formulation of penciclovir. It was first licensed in 19941 and since then has been approved in a number of countries, including the United States, for the treatment of acute herpes zoster, acute recurrent and primary genital herpes, and suppression of genital herpes recurrences. In addition, Denavir, a topical formulation of penciclovir, has been approved for treatment of herpes labialis cold sores. Famciclovir and the intravenous formulation, penciclovir, have recently been granted regulatory approval in Europe for treatment of herpesvirus (i.e. varicella zoster virus, herpes simplex virus) infections in immunocompromised hosts.